




3D-SHAPER

CE
2797

FDA
510(k)
K220822


Reveals cortical &
trabecular bone from DXA

3D-Shaper®: Turning DXA into a 3D Medical Device



- Measure **cortical & trabecular** bone separately
- **Fully automated** 3D analysis and report
- Easy **monitoring of bone health** over time
- **Retrospective** data analysis
- No additional scan **time** or **radiation dose**

Easily integrated into the clinical workflow



*3D-Shaper® may vary in features and capabilities in the USA

3D-Shaper®: Impacting the entire clinical pathway

DXA aBMD



+



3D-SHAPER

Bone Health
Evaluation

Fracture Risk
Prediction

Treatment
Selection

Treatment
Monitoring

Drug Holiday/
Cessation

Cortical and trabecular bone both need to be considered to fully understand and accurately evaluate the bone health of your patients.

This knowledge is a vital step in helping to optimize treatment selection and accurately monitor the effect of your therapy. 3D-Shaper® provides you with a clear rationale for individualized patient care - helping you give patients the right treatment first time, every time.

3D-Shaper® is indicated for assisting the diagnosis and monitoring of bone health, bone disorders such as primary or secondary osteoporosis and for the monitoring of treatment effects.

3D-Shaper®: Supporting treatment selection

① Understanding how medications impact bone health helps you prescribe a treatment **best suited to your patients' needs**

	2D DXA	3D-Shaper	
	aBMD	Trabecular vBMD	Cortical sBMD
Alendronate ^{3,7,8}	+	+	+
Denosumab ^{7,8,9}	++	++	++
Zoledronic acid ⁹	+	+	++
Teriparatide ^{1,2,4,7}	+	++	=
Abaloparatide ^{1,2,4}	++	++	++
Romosozumab ^{5,6}	+++	+++	+++

Research highlighting changes in bone health after 12 to 24 months of different treatment medications

1 - Winzenrieth R, et al. JBMR Plus, 2022, Jan. Accepted Author Manuscript. e10612. <https://pubmed.ncbi.nlm.nih.gov/36434451/>

2 - Winzenrieth R et al. J Clin Densitom, 2021 Aug 31 at JCOO 1287, S1094-8950(21)00098-6. <https://pubmed.ncbi.nlm.nih.gov/35033435/>

3 - Lopez Picazo M et al. The effects of Parathyroid hormone and alendronate alone or in combination on trabecular and cortical bone using DXA-based 3D -modelling. ASBMR 2021

4 - Winzenrieth R, et al. Osteoporos Int, 2021 Jan 26. <https://pubmed.ncbi.nlm.nih.gov/33486831/>

5 - Tomoko Kato, Motokazu Kaji, Ikuo Tanaka, et al. Investigation of therapeutic effect of Romosozumab using 3D - SHAPER. JDS & JBMR 2021.

6 - Yohei Asada, et al. Change of bone mass after 1 year treatment with Romosozumab evaluated by 3D - SHAPER, a novel image analysis software. JDS & JBMR 2021.




7 - Winzenrieth R, et al. Osteoporos Int, 2018 Oct;28(10):2323-2333. DOI: 10.1007/s00198-018-4924-4. <https://pubmed.ncbi.nlm.nih.gov/29571413/>

8 - Almojaya M et al. 3D Modelling of hip DXA indicates cortical vBMD superior efficacy of denosumab versus alendronate. ASBMR 2018

9 - Core Molina F, et al. Cortical and Trabecular Bone Response in Proximal Femur from Women with Osteoporosis Treated with Denosumab or Zoledronic Acid using 3D Modelling Techniques obtained from DXA. ASBMR 2018

3D-Shaper[®]: Providing the full picture of bone health

② Enhance patient care with **optimized, targeted treatment selection** and **accurate monitoring of response***



Patient-Specific
Target





Evidence-Based
Treatment



Monitor Treatment
Response

*3D-Shaper[®] may vary in features and capabilities in the USA

3D-Shaper®: The ONLY medical imaging software for 3D evaluation of bone health from DXA



C R E A T I N G 3 D M O D E L

Learn more at www.3d-shaper.com

Contact info@3d-shaper.com